LL-37 Antimicrobial & Wound Healing Protocols — Research Design

LL-37 is one of the most versatile host defense peptides in preclinical research, bridging antimicrobial activity, wound repair, and immunomodulation. But its amphipathic structure creates unique handling challenges — particularly aggregation at neutral pH — and its dual-mode activity demands careful experimental design. This guide covers practical protocols for antimicrobial testing, wound healing models, reconstitution strategies, and research design controls that distinguish LL-37-specific effects from charge artifacts or endotoxin contamination.

Wound Healing Mechanism: EGFR Transactivation and Keratinocyte Migration

LL-37 accelerates wound closure primarily through FPR2-mediated EGFR transactivation. When LL-37 binds FPR2 on keratinocytes, it activates matrix metalloproteinases (MMPs) that cleave membrane-bound EGFR ligands (HB-EGF, amphiregulin) into their soluble forms. These shed ligands engage EGFR in autocrine/paracrine loops, triggering ERK1/2 and Src kinase signaling that drives directional cell migration into the wound bed.

Scratch assay data show that 1 mcg/mL LL-37 accelerates keratinocyte wound closure by 40-60% at 24h compared to untreated controls. This is not just proliferation — it's directional migration. In porcine partial-thickness wound models (Heilborn 2003, J Invest Dermatol), topical LL-37 accelerated re-epithelialization by ~33% at day 4 post-injury. Importantly, this effect is blocked by AG1478 (EGFR inhibitor) but not by PI3K inhibitors alone, establishing EGFR as the dominant proximal node.

Macrophage M2 Polarization in Wound Context

Beyond epithelialization, LL-37 shapes the wound inflammatory environment by promoting M2 macrophage polarization. M2 macrophages (anti-inflammatory/pro-resolution phenotype) express high levels of CD206, Arg1, and IL-10, and drive collagen deposition and angiogenesis during wound maturation. LL-37 at 0.5-2 mcg/mL shifts bone marrow-derived macrophages (BMDMs) toward M2 markers via FPR2/STAT6 signaling, reducing IL-12p40 and TNF-alpha secretion while increasing IL-10 and TGF-beta1 output.

In excisional wound models, LL-37-treated wounds show increased CD206+ macrophages at day 5 and accelerated granulation tissue formation compared to vehicle. This M2-skewing effect is mechanistically distinct from its direct antimicrobial function and represents a separate research endpoint.

Wound Healing Model Protocols

Excisional Dorsal Skin Wound (Standard Model)

• Mice: 8-12 week C57BL/6J or BALB/c, shaved dorsum 24h prior
• Wound: 6mm biopsy punch, full-thickness through panniculus carnosus, two wounds per mouse (bilateral)
• LL-37 dosing: Topical application of 10-50 mcg in 20 mcL sterile PBS at day 0 immediately post-wounding and day 2; vehicle control is 20 mcL PBS only
• Harvest: Days 3, 5, 7, 10 for histology (H&E, Masson's trichrome), immunofluorescence (K14 for keratinocytes, CD31 for vessels, CD206 for M2 macrophages), and wound area planimetry
• Endpoints: Re-epithelialization percentage (measured as neoepithelial tongue length / original wound diameter), granulation tissue thickness, collagen density (trichrome quantification), vessel density (CD31+ area)

Diabetic Wound Model (ob/ob or db/db Mice)

Diabetic wounds show impaired LL-37 expression and delayed healing. Use ob/ob (leptin-deficient) or db/db (leptin receptor-deficient) mice on C57BL/6 background, age 10-14 weeks with confirmed hyperglycemia (fasting glucose >250 mg/dL). The same excisional protocol applies, but healing is delayed by ~50% in vehicle-treated diabetics. LL-37 at 25-50 mcg per wound partially rescues re-epithelialization — a ~30% improvement over diabetic vehicle at day 7. This model is valuable for testing LL-37 therapeutic potential in impaired healing contexts.

Subcutaneous Injection Model (Dermal Matrix Formation)

For studying dermal repair without epithelial confounds, inject LL-37 (10-50 mcg per site) subcutaneously in 100 mcL PBS or Matrigel suspension. Harvest at days 7-14 and assess collagen I deposition by picrosirius red staining, fibroblast infiltration (vimentin IHC), and vascularization (CD31). This isolates dermal fibroblast and angiogenic responses from keratinocyte-driven re-epithelialization.

Antimicrobial Research Protocols: MIC Determination

LL-37's antimicrobial activity is concentration- and pathogen-dependent. Minimum inhibitory concentration (MIC) testing is the foundational assay:

Broth Microdilution MIC (CLSI-Adapted)

• Prepare LL-37 stock at 256 mcg/mL in 0.01% acetic acid; perform 2-fold serial dilutions in cation-adjusted Mueller-Hinton broth (CAMHB) — critical because divalent cations affect AMP activity
• Bacterial strains: ATCC reference strains (S. aureus ATCC 29213, E. coli ATCC 25922, P. aeruginosa ATCC 27853) grown to mid-log phase (OD600 ~0.5), dilute to 5x10^5 CFU/mL in CAMHB
• Plate setup: 96-well polypropylene plate (low-binding), 50 mcL peptide dilution + 50 mcL bacterial suspension per well, final inoculum 2.5x10^5 CFU/mL
• Incubate: 16-20h at 37C with orbital shaking (100 rpm)
• MIC readout: Lowest LL-37 concentration with no visible turbidity; confirm by plating 10 mcL onto agar and counting CFU (should be <0.1% of inoculum)

Expected MIC ranges from the literature (Nizet 2001, J Immunol; Turner 1998, Antimicrob Agents Chemother): S. aureus 2-8 mcg/mL, E. coli 0.5-4 mcg/mL, P. aeruginosa 8-16 mcg/mL (planktonic). Gram-positive MICs are higher due to thicker peptidoglycan layers that reduce peptide access to the cytoplasmic membrane.

Biofilm Disruption Assay

LL-37 disrupts established biofilms at sub-MIC concentrations by interfering with quorum sensing and matrix integrity. Use the Calgary Biofilm Device or 96-well peg lid model: grow biofilms on pegs or well bottoms for 24-48h in tryptic soy broth + 1% glucose, then treat mature biofilms with LL-37 (0.1-10 mcg/mL) for 4-24h. Quantify viable biofilm bacteria by sonication + CFU plating, or by crystal violet staining (biomass) and XTT reduction (viability). LL-37 at 1-2 mcg/mL reduces P. aeruginosa biofilm CFU by ~70-80% at 24h (Overhage 2008, Infect Immun).

Checkerboard Assay with Antibiotics

To assess synergy between LL-37 and conventional antibiotics (e.g., gentamicin, vancomycin, ciprofloxacin), perform a checkerboard microdilution: set up a 2D grid with LL-37 concentrations on one axis (0.125x to 4x MIC) and antibiotic on the other. Calculate fractional inhibitory concentration index (FICI). FICI ≤0.5 indicates synergy. LL-37 shows synergy with aminoglycosides (gentamicin) against P. aeruginosa and S. aureus by facilitating antibiotic membrane penetration.

Reconstitution Challenge: Preventing Aggregation

LL-37's amphipathic helix drives self-association in aqueous buffer, forming oligomers, fibrils, and aggregates that alter receptor binding and antimicrobial potency. Aggregation is the most common source of irreproducibility in LL-37 research.

Recommended Reconstitution Protocol

• Reconstitute lyophilized LL-37 at 1 mg/mL in 0.01% acetic acid (pH ~4.5-5.5). Low pH protonates histidine and reduces helix stability, minimizing aggregation.
• Alternatively, for cell culture applications where acid is problematic: dissolve in sterile water + DMSO (<0.1% final DMSO in culture media), then dilute immediately into PBS or media. DMSO disrupts hydrophobic clustering.
• Never reconstitute directly in neutral PBS or HBSS at high concentration (>100 mcg/mL) — this reliably produces aggregates within 30-60 minutes at room temperature.
• Prepare working dilutions fresh before each experiment. Do not store LL-37 in neutral buffer for >4h at room temperature or >24h at 4C.
• For long-term storage: aliquot 1 mg/mL stock in 0.01% acetic acid into single-use 10-20 mcL aliquots, freeze at -20C, avoid repeated freeze-thaw cycles (limit to 2 cycles maximum).
• Visual check: The solution should be clear and colorless. Opalescence or particulates indicate aggregation — discard.

Aggregation can be formally assessed by dynamic light scattering (DLS) or size-exclusion chromatography. Monomeric LL-37 has a hydrodynamic radius ~1.5-2 nm; aggregates appear as >10 nm particles. If your lab lacks DLS, turbidity measurement at 400 nm (A400 should be <0.05 for a 50 mcg/mL solution) serves as a rough aggregation screen.

Storage Stability and Handling

• Lyophilized powder: Stable at -20C for ≥2 years in desiccated conditions. Minimize exposure to humidity during weighing.
• Reconstituted stock (0.01% acetic acid, 1 mg/mL): -20C single-use aliquots stable for 6-12 months; avoid freeze-thaw.
• Working solution stability: In culture media (pH 7.4, 37C), LL-37 retains >90% activity for 24-48h. Beyond 48h, activity declines due to proteolytic degradation by serum proteases and peptide adsorption to plastic.
• Avoid polystyrene tubes for storage — use polypropylene (low-binding) to minimize surface loss. LL-37 adheres strongly to polystyrene at low concentrations (<1 mcg/mL).

Research Design Considerations and Controls

• Scrambled peptide control: Synthesize a scrambled 37-aa peptide with identical amino acid composition but randomized sequence. This control distinguishes amphipathic helix-dependent effects (structure-specific) from nonspecific charge effects.
• EGFR inhibitor dissection: In wound healing experiments, include an AG1478 (EGFR inhibitor, 1 mcM) co-treatment group. If LL-37's effect is blocked by AG1478, EGFR transactivation is the dominant mechanism. If not, FPR2 is signaling through alternative pathways (PI3K, Akt).
• M2 polarization validation: Dual-stain for CD206 (M2 marker) and iNOS (M1 marker) on wound macrophages. LL-37 should increase CD206+/iNOS- cells and decrease iNOS+/CD206- cells. Single-marker analysis is insufficient — M1/M2 is a spectrum, not a binary.
• Endotoxin testing: LL-37 from bacterial expression or SPPS resin can carry LPS contamination. Run LAL (Limulus amebocyte lysate) assay on each batch. Endotoxin >0.1 EU/mL can independently drive TLR4 signaling and confound immunomodulatory readouts.
• FPR2 antagonist control: WRW4 (10 mcM) blocks FPR2. If LL-37's effect persists in the presence of WRW4, the mechanism is FPR2-independent (possibly direct membrane effects or TLR4 engagement).
• Species caveat: Murine cathelicidin (CRAMP) and human LL-37 share ~67% homology but have different FPR2 binding affinities. If using LL-37 in mouse models, confirm that human LL-37 binds murine FPR2 (it does, but with ~2-3-fold lower affinity than to human FPR2).

Summary: Key Takeaways for Robust LL-37 Research

• Reconstitute in acidic buffer (0.01% acetic acid) to prevent aggregation; prepare working dilutions fresh.
• Use scrambled peptide and FPR2/EGFR antagonist controls to establish mechanism specificity.
• For wound healing: quantify both re-epithelialization (K14 immunofluorescence) and M2 macrophage infiltration (CD206+ cell counts).
• For antimicrobial work: report MIC in cation-adjusted broth and test biofilm disruption separately from planktonic MIC.
• Always test for endotoxin contamination — it's the most common confounder in LL-37 immunomodulation studies.